Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intoplicine
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Intoplicine is a pyrido[4,3-b]indole derivative that acts as a dual inhibitor of DNA topoisomerase I and II. It was developed as an antitumor agent and has shown activity against various solid tumors in preclinical models. Intoplicine works by inhibiting DNA nicking and closing reactions, stabilizing the cleavable complex formed during the religation reaction involving topoisomerase I and II and DNA. It was initially developed by Rhone-Poulenc Sante (now part of Sanofi) but its clinical development was discontinued.
- Other names
- RP-60475RP60475RP 60475NSC 645008NSC645008NSC-645008
02
Targets
DNATOP1MT (Mitochondrial topoisomerase I)TOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Intoplicine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intoplicine.